Literature DB >> 27073521

miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer.

Wenqi Ma1, Qiang Yu2, Jue Jiang1, Xiaopeng DU1, Lili Huang1, Linlin Zhao1, Q I Zhou1.   

Abstract

Colorectal cancer (CRC) is a highly invasive tumor that is frequently associated with distant metastasis, which is the primary cause of poor prognosis. However, the mechanisms of metastasis remain poorly understood. MicroRNAs (miRNAs/miRs) have been considered to be implicated in CRC progression. In particular, miR-517a is proposed as a novel tumor-associated miRNA and has a potential role in tumor metastasis. The expression of miR-517a in CRC specimens was detected by reverse transcription-quantitative polymerase chain reaction. Transwell assays were performed to determine the migration and invasion of CRC cells. The putative target genes of miR-517a were disclosed using publicly available databases and western blot analysis. The present study identified that the expression of miR-517a was significantly higher in CRC tissues as compared with adjacent non-tumor tissues. Clinical analysis indicated that increased expression of miR-517a was correlated with poor prognostic features and poor long-term survival of CRC patients. In vitro evidences demonstrated that downregulation of miR-517a inhibited cell migration and invasion in HCT-116 cells. By contrast, upregulation of miR-517a increased the number of migrated and invaded SW480 cells. Notably, miR-517a expression was inversely regulated by forkhead box J3 (FOXJ3) abundance in CRC cells. Furthermore, an inverse correlation between miR-517a and FOXJ3 expression was observed in CRC tissues. In conclusion, miR-517a appears to be an independent prognostic marker for predicting survival of CRC patients, and may promote cell migration and invasion by inhibiting FOXJ3.

Entities:  

Keywords:  colorectal cancer; invasion; miR-517a; migration; prognostic marker

Year:  2016        PMID: 27073521      PMCID: PMC4812169          DOI: 10.3892/ol.2016.4269

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

Review 1.  MicroRNA dysregulation in gastric cancer: a new player enters the game.

Authors:  W K K Wu; C W Lee; C H Cho; D Fan; K Wu; J Yu; J J Y Sung
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

2.  MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer.

Authors:  Tommaso Colangelo; Alessandra Fucci; Carolina Votino; Lina Sabatino; Massimo Pancione; Carmelo Laudanna; Monica Binaschi; Mario Bigioni; Carlo Alberto Maggi; Domenico Parente; Nicola Forte; Vittorio Colantuoni
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

3.  MiR-517a-3p accelerates lung cancer cell proliferation and invasion through inhibiting FOXJ3 expression.

Authors:  Jingpeng Jin; Shanshan Zhou; Changfeng Li; Ruisi Xu; Lingling Zu; Jiacong You; Bin Zhang
Journal:  Life Sci       Date:  2014-05-17       Impact factor: 5.037

4.  An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma.

Authors:  Junjie Feng; Seong-Tae Kim; Wennuan Liu; Jin Woo Kim; Zheng Zhang; Yi Zhu; Michael Berens; Jielin Sun; Jianfeng Xu
Journal:  Cancer       Date:  2011-06-28       Impact factor: 6.860

5.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

6.  Is the seventh edition of the UICC/AJCC TNM staging system reasonable for patients with tumor deposits in colorectal cancer?

Authors:  Lin-lin Tong; Peng Gao; Zhen-ning Wang; Yong-xi Song; Ying-ying Xu; Zhe Sun; Cheng-zhong Xing; Hui-mian Xu
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

Review 7.  MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.

Authors:  Shan Muhammad; Kavanjit Kaur; Rui Huang; Qian Zhang; Paviter Kaur; Hamza Obaid Yazdani; Muhammad Umar Bilal; Jiang Zheng; Liu Zheng; Xi-Shan Wang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase.

Authors:  Rui-Min Chang; Hao Yang; Feng Fang; Jiang-Feng Xu; Lian-Yue Yang
Journal:  Hepatology       Date:  2014-08-21       Impact factor: 17.425

9.  MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma.

Authors:  Kangsheng Tu; Xin Zheng; Changwei Dou; Chao Li; Wei Yang; Yingmin Yao; Qingguang Liu
Journal:  Int J Mol Sci       Date:  2014-11-07       Impact factor: 5.923

10.  microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer.

Authors:  Lijing Zhang; Yujuan Dong; Nana Zhu; Ho Tsoi; Zengren Zhao; Chung Wah Wu; Kunning Wang; Shu Zheng; Simon Sm Ng; Francis Kl Chan; Joseph Jy Sung; Jun Yu
Journal:  Mol Cancer       Date:  2014-05-26       Impact factor: 27.401

View more
  17 in total

1.  MicroRNA-19b promotes the migration and invasion of ovarian cancer cells by inhibiting the PTEN/AKT signaling pathway.

Authors:  Dan-Tong Liu; Hai-Rong Yao; Yan-Ying Li; Yang-Yang Song; Meng-Ya Su
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

2.  Association between the overexpression of PBOV1 and the prognosis of patients with hepatocellular carcinoma.

Authors:  Chengbiao Xue; Zibiao Zhong; Shaojun Ye; Yanfeng Wang; Qifa Ye
Journal:  Oncol Lett       Date:  2018-06-25       Impact factor: 2.967

3.  Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.

Authors:  Igor Lopes Dos Santos; Karlla Greick Batista Dias Penna; Megmar Aparecida Dos Santos Carneiro; Larisse Silva Dalla Libera; Jéssica Enocencio Porto Ramos; Vera Aparecida Saddi
Journal:  Mol Biol Rep       Date:  2021-02-17       Impact factor: 2.316

4.  Expression of EZH2 is associated with poor outcome in colorectal cancer.

Authors:  Zhuanpeng Chen; Ping Yang; Wanglin Li; Feng He; Jianchang Wei; Tong Zhang; Junbin Zhong; Huacui Chen; Jie Cao
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

5.  MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.

Authors:  Yongpeng Xie; Xin Ma; Luyao Chen; Hongzhao Li; Liangyou Gu; Yu Gao; Yu Zhang; Xintao Li; Yang Fan; Jianwen Chen; Xu Zhang
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

6.  Non-digestible carbohydrates supplementation increases miR-32 expression in the healthy human colorectal epithelium: A randomized controlled trial.

Authors:  Fiona C Malcomson; Naomi D Willis; Iain McCallum; Long Xie; Bart Lagerwaard; Seamus Kelly; D Michael Bradburn; Nigel J Belshaw; Ian T Johnson; John C Mathers
Journal:  Mol Carcinog       Date:  2017-05-09       Impact factor: 4.784

7.  Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma.

Authors:  Marco Maugeri; Davide Barbagallo; Cristina Barbagallo; Barbara Banelli; Stefania Di Mauro; Francesco Purrello; Gaetano Magro; Marco Ragusa; Cinzia Di Pietro; Massimo Romani; Michele Purrello
Journal:  Oncotarget       Date:  2016-12-13

Review 8.  MicroRNAs as regulators and mediators of forkhead box transcription factors function in human cancers.

Authors:  Chen Li; Kai Zhang; Jing Chen; Longbang Chen; Rui Wang; Xiaoyuan Chu
Journal:  Oncotarget       Date:  2017-02-14

9.  Selective activation of miRNAs of the primate-specific chromosome 19 miRNA cluster (C19MC) in cancer and stem cells and possible contribution to regulation of apoptosis.

Authors:  Phan Nguyen Nhi Nguyen; Chiu-Jung Huang; Shigeki Sugii; Soon Keng Cheong; Kong Bung Choo
Journal:  J Biomed Sci       Date:  2017-03-07       Impact factor: 8.410

10.  Prognostic value of microRNAs in colorectal cancer: a meta-analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Rong Wu; Yue Zhang; Zhen-Yong Zhang
Journal:  Cancer Manag Res       Date:  2018-04-30       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.